The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis

Inclusion Criteria: * 1\. Primary osteoarthritis of the hip defined according to the ACR criteria; symptomatic, 2. Osteoarthritis of radiological grade II to III according to the Kellgren-Lawrence classification, using X-rays performed during the last three months, 3. Overall pain intensity between 40 and 80 mm on a VAS of 100 mm at the pre-screening examination, 4. The patients experienced pain at least one in two days during the last 30 days, it was resistant to paracetamol treatment at a dose of 4 g/day and a step 2 analgesic or a NSAID taken for at least 10 days, 5. A prosthesis is not planned in the next six months. Exclusion Criteria: * Women who are pregnant or breastfeeding or women who could become pregnant and are not using effective contraception, * Major dysplasia (defined using Lequesne's criteria as dislocation of the hip), * Treatment by intra-articular injection of hyaluronic acid in the symptomatic hip during the 6 months prior to pre-screening, * Patients with a history of hypersensitivity to any of the ingredients in the hyaluronan, * The presence of inflammatory arthropathy or another disorder or condition that could affect the joint (e.g., rheumatoid arthritis, metabolic bone disease, femoral head necrosis, psoriasis, gout, infection), * Another muscular or skeletal condition that could interfere with the evaluation of the efficacy of the treatment on the hip in question (evaluation of pain or functional handicap), * Systemic corticosteroid therapy or intra-articular injection of corticosteroids into the ipsilateral hip or knee within the last month, * Intermittent claudication or vascular disease, * Previous surgery on the hip in question, * Septic arthritis at any site, * Any surgical procedure, including arthroplasty or arthroscopy, to the hip during the six months prior to pre-screening or surgery scheduled during the trial, * Any chronic skin condition that could affect the site of the injection, * Use of the investigational treatment or material during the last three months, * Oral or injectable anticoagulant treatment, * Antiaggregant platelet treatment, particularly low-dose aspirin, * Symptomatic chondrocalcinosis in the painful hip